Economic consequences of surfactant therapy. - Suppr | 超能文献

Economic consequences of surfactant therapy.

作者信息

Eidelman A I

机构信息

Department of Neonatology, Shaare Zedek Medical Center, Hebrew University-Hadassah Medical School, Jerusalem, Israel.

出版信息

J Perinatol. 1993 Mar-Apr;13(2):137-9.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Economic consequences of surfactant therapy.

J Perinatol. 1993 Mar-Apr;13(2):137-9.

2

Impact of surfactant treatment on cost of neonatal intensive care: a cost-benefit analysis.

J Perinatol. 1990 Dec;10(4):416-9.

3

Cost effectiveness of prevention and treatment of neonatal respiratory distress (RDS) with exogenous surfactant: what has changed in the last three decades?外源性表面活性剂预防和治疗新生儿呼吸窘迫综合征（RDS）的成本效益：过去三十年有哪些变化？

Early Hum Dev. 2006 Feb;82(2):105-15. doi: 10.1016/j.earlhumdev.2006.01.005. Epub 2006 Feb 7.

4

Surfactant replacement therapy.

Indian Pediatr. 1998 Nov;35(11):1081-96.

5

Exogenous surfactant in neonatal respiratory distress syndrome.外源性表面活性物质在新生儿呼吸窘迫综合征中的应用

R I Med. 1995 Jan;78(1):7-10.

6

Surfactant and the neonatal lung.表面活性剂与新生儿肺脏

Br J Hosp Med. 1997;58(8):381-4, 397.

7

Economic outcome for intensive care of infants of birthweight 500-999 g born in Victoria in the post surfactant era. The Victorian Infant Collaborative Study Group.后表面活性剂时代维多利亚州出生体重500 - 999克婴儿重症监护的经济结果。维多利亚州婴儿协作研究小组。

J Paediatr Child Health. 1997 Jun;33(3):202-8.

8

Use of surfactant for respiratory distress syndrome.表面活性剂用于治疗呼吸窘迫综合征。

Neonatal Netw. 1999 Oct;18(7):43.

9

Surfactant replacement therapy: a second look.表面活性剂替代疗法：再审视

Neonatal Netw. 1990 Oct;9(3):79-81.

10

Economic impact of porcine surfactant replacement (Curosurf) for severe neonatal respiratory distress syndrome.猪肺表面活性物质替代疗法（珂立苏）对重症新生儿呼吸窘迫综合征的经济影响

J Perinat Med. 1991;19 Suppl 1:403-7. doi: 10.1515/jpme.1991.19.5.403.

引用本文的文献

1

A pharmacoeconomic analysis of in-hospital costs resulting from reintubation in preterm infants treated with lucinactant, beractant, or poractant alfa.对接受卢西纳可、贝拉克坦或泊拉坦阿尔法治疗的早产儿再次插管导致的住院费用进行的药物经济学分析。

J Pediatr Pharmacol Ther. 2012 Jul;17(3):220-7. doi: 10.5863/1551-6776-17.3.220.

2

Economic outcomes of colfosceril palmitate rescue therapy in infants weighing 1250g or more with respiratory distress syndrome: results from a randomised trial.

Pharmacoeconomics. 1994 Oct;6(4):358-69. doi: 10.2165/00019053-199406040-00003.

3

A risk-benefit assessment of natural and synthetic exogenous surfactants in the management of neonatal respiratory distress syndrome.天然和合成外源性表面活性剂治疗新生儿呼吸窘迫综合征的风险效益评估

Drug Saf. 1998 May;18(5):321-37. doi: 10.2165/00002018-199818050-00002.